Literature DB >> 9590660

Quantitative assessment of hematopoietic chimerism after allogeneic bone marrow transplantation has predictive value for the occurrence of irreversible graft failure and graft-vs.-host disease.

M Gyger1, C Baron, L Forest, P Lussier, F Lagacé, I Bissonnette, R Bélanger, Y Bonny, L Busque, D C Roy, C Perreault.   

Abstract

Primary graft failure, secondary to either host-vs.-graft reaction or delayed engraftment, and graft-vs.-host disease (GVHD) are among the most difficult clinical problems to manage in the field of allogeneic bone marrow transplantation (BMT). Early diagnosis of both conditions would greatly improve their outcome. Using fluorescence in situ hybridization (FISH) with an X- and Y-probe mixture, we sequentially monitored chimerism of neutrophils and lymphoid cells from day 1 to 100 in 28 consecutive recipients of sex-mismatched unmanipulated bone marrow grafts. The objective was to quantitatively assess the evolution of chimerism during this crucial time interval and to determine whether chimerism patterns would be predictive of engraftment and GVHD. In recipients with primary graft failure (n=7), the presence of donor-type neutrophils and NK cells as well as the predominance of donor-type T cells distinguished patients who responded to G-CSF (n=5) from nonresponders (n=2). Furthermore, the clearance of host CD3+CD56- cells during days 5-10 posttransplantation was significantly hastened in patients who subsequently developed acute (delta=80%) or chronic (delta=81%) GVHD compared with patients without GVHD (delta=17%). Thus, our data suggest that molecular monitoring of the fate of host/donor hematopoietic cells in the early posttransplantation period could be useful in differentiating patients with delayed engraftment from those with irreversible rejection and in predicting the occurrence of GVHD as soon as day 10. This investigational approach may provide an appropriate basis on which to select adequate treatment for primary graft failure and high-risk candidates that could benefit from novel preemptive therapies for GVHD.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9590660

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  4 in total

1.  Droplet Digital PCR-Based Chimerism Analysis for Primary Immunodeficiency Diseases.

Authors:  Tsubasa Okano; Yuki Tsujita; Hirokazu Kanegane; Kanako Mitsui-Sekinaka; Kay Tanita; Satoshi Miyamoto; Tzu-Wen Yeh; Motoi Yamashita; Naomi Terada; Yumi Ogura; Masatoshi Takagi; Kohsuke Imai; Shigeaki Nonoyama; Tomohiro Morio
Journal:  J Clin Immunol       Date:  2018-04-18       Impact factor: 8.317

2.  Risk factors and outcome of graft failure after HLA matched and mismatched unrelated donor hematopoietic stem cell transplantation: a study on behalf of SFGM-TC and SFHI.

Authors:  T Cluzeau; J Lambert; N Raus; K Dessaux; L Absi; F Delbos; A Devys; M De Matteis; V Dubois; M Filloux; M Fort; F Hau; I Jollet; M Labalette; D Masson; B Mercier; B Pedron; P Perrier; C Picard; F Quainon; A Ramounau-Pigot; V Renac; P Van Endert; D Charron; R Peffault de la Tour; J L Taupin; P Loiseau
Journal:  Bone Marrow Transplant       Date:  2016-02-08       Impact factor: 5.483

3.  Impact of hematopoietic chimerism at day +14 on engraftment after unrelated donor umbilical cord blood transplantation for hematologic malignancies.

Authors:  Federico Moscardó; Jaime Sanz; Leonor Senent; Susana Cantero; Javier de la Rubia; Pau Montesinos; Dolores Planelles; Ignacio Lorenzo; Jose Cervera; Javier Palau; Miguel A Sanz; Guillermo F Sanz
Journal:  Haematologica       Date:  2009-06       Impact factor: 9.941

4.  Primary graft failure, but not relapse, may be identified by early chimerism following double cord blood unit transplantation.

Authors:  Rachael Hough; Andre Lopes; Pip Patrick; Nigel Russell; Kavita Raj; Eleni Tholouli; John A Snowden; Matthew Collin; Nadjet El-Mehidi; Anthony Lawrie; Laura Clifton-Hadley; Paul Veys; Charles Craddock; Stephen Mackinnon; Gordon Cook; Bronwen Shaw; David Marks
Journal:  Blood Adv       Date:  2022-04-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.